Linked Data API

Show Search Form

Search Results

1126878
star this property registered interest false more like this
star this property date less than 2019-05-15more like thismore than 2019-05-15
star this property answering body
Department of Health and Social Care more like this
star this property answering dept id 17 more like this
star this property answering dept short name Health and Social Care more like this
star this property answering dept sort name Health and Social Care more like this
star this property hansard heading NHS: Cybercrime more like this
star this property house id 1 more like this
star this property legislature
25259
star this property pref label House of Commons more like this
star this property question text To ask the Secretary of State for Health and Social Care, what steps he has taken to ensure that NHS England is prepared to defend the NHS against cyber attacks. more like this
star this property tabling member constituency Windsor more like this
star this property tabling member printed
Adam Afriyie more like this
star this property uin 254786 more like this
star this property answer
answer
unstar this property is ministerial correction false more like this
unstar this property date of answer less than 2019-05-24more like thismore than 2019-05-24
star this property answer text <p>The information requested on cyber spending covers sensitive detail about cyber security investment for the National Health Service. In this instance, releasing this information at the level of any annual breakdown may assist in determining the effectiveness of detecting cyber-attacks on the NHS, and could compromise measures to protect NHS IT systems, leaving them vulnerable to future cyber-attacks.</p><p>However, in total, over £250 million will have been invested nationally to improve the cyber security of the health and care system between 2016 and 2021. This excludes both investment by local organisations, and wider national IT investment which supports better security such as Microsoft licensing for NHS organisations.</p><p>Regarding the steps taken to defend against cyber attacks on the NHS, the active cyber defence of NHS organisations is a local responsibility for each organisation to carry out. However, there is national support and practical guidance available to NHS organisations which is primarily delivered by NHS Digital but supported and prioritised for the highest risk organisations by NHS England and the Department. In the event of national-scale incidents that affect many health and care organisations, NHS Digital plays a vital role in coordinating and ensuring appropriate technical remediation, as part of the wider cross-system cyber security response led by the Department.</p>
star this property answering member constituency Thurrock remove filter
star this property answering member printed Jackie Doyle-Price more like this
star this property grouped question UIN 254785 more like this
star this property question first answered
less than 2019-05-24T12:33:05.713Zmore like thismore than 2019-05-24T12:33:05.713Z
star this property answering member
4065
star this property label Biography information for Jackie Doyle-Price more like this
star this property tabling member
1586
unstar this property label Biography information for Adam Afriyie more like this
1126877
star this property registered interest false more like this
star this property date less than 2019-05-15more like thismore than 2019-05-15
star this property answering body
Department of Health and Social Care more like this
star this property answering dept id 17 more like this
star this property answering dept short name Health and Social Care more like this
star this property answering dept sort name Health and Social Care more like this
star this property hansard heading NHS: Cybercrime more like this
star this property house id 1 more like this
star this property legislature
25259
star this property pref label House of Commons more like this
star this property question text To ask the Secretary of State for Health and Social Care, how much the National Health Service spent on cyber security in each of the last five years. more like this
star this property tabling member constituency Windsor more like this
star this property tabling member printed
Adam Afriyie more like this
star this property uin 254785 more like this
star this property answer
answer
unstar this property is ministerial correction false more like this
unstar this property date of answer less than 2019-05-24more like thismore than 2019-05-24
star this property answer text <p>The information requested on cyber spending covers sensitive detail about cyber security investment for the National Health Service. In this instance, releasing this information at the level of any annual breakdown may assist in determining the effectiveness of detecting cyber-attacks on the NHS, and could compromise measures to protect NHS IT systems, leaving them vulnerable to future cyber-attacks.</p><p>However, in total, over £250 million will have been invested nationally to improve the cyber security of the health and care system between 2016 and 2021. This excludes both investment by local organisations, and wider national IT investment which supports better security such as Microsoft licensing for NHS organisations.</p><p>Regarding the steps taken to defend against cyber attacks on the NHS, the active cyber defence of NHS organisations is a local responsibility for each organisation to carry out. However, there is national support and practical guidance available to NHS organisations which is primarily delivered by NHS Digital but supported and prioritised for the highest risk organisations by NHS England and the Department. In the event of national-scale incidents that affect many health and care organisations, NHS Digital plays a vital role in coordinating and ensuring appropriate technical remediation, as part of the wider cross-system cyber security response led by the Department.</p>
star this property answering member constituency Thurrock remove filter
star this property answering member printed Jackie Doyle-Price more like this
star this property grouped question UIN 254786 more like this
star this property question first answered
less than 2019-05-24T12:33:05.65Zmore like thismore than 2019-05-24T12:33:05.65Z
star this property answering member
4065
star this property label Biography information for Jackie Doyle-Price more like this
star this property tabling member
1586
unstar this property label Biography information for Adam Afriyie more like this
999254
star this property registered interest false more like this
star this property date less than 2018-10-31more like thismore than 2018-10-31
star this property answering body
Department of Health and Social Care more like this
star this property answering dept id 17 more like this
star this property answering dept short name Health and Social Care more like this
star this property answering dept sort name Health and Social Care more like this
star this property hansard heading Mental Illness: Employment more like this
star this property house id 1 more like this
star this property legislature
25259
star this property pref label House of Commons more like this
star this property question text To ask the Secretary of State for Health and Social Care, how many additional people he estimates will retain employment as a result of the individual placement support programme in (a) Windsor and (b) the South East by 2023-24. more like this
star this property tabling member constituency Windsor more like this
star this property tabling member printed
Adam Afriyie more like this
star this property uin 186281 more like this
star this property answer
answer
unstar this property is ministerial correction false more like this
unstar this property date of answer less than 2018-11-07more like thismore than 2018-11-07
star this property answer text <p>Individual Placement and Support (IPS) is a National Institute for Health and Care Excellence-approved model of employment support designed to help individuals with severe and enduring mental illness (SMI) get into, and stay in work.</p><p> </p><p>United Kingdom IPS provision has grown in recent years and the Government is committed to a further expansion. In the 2018 Budget the Chancellor announced that the National Health Service will expand IPS services to help patients with SMI, benefitting 55,000 people by 2023-24.</p><p> </p><p>We are not able to forecast at this stage how many people will be supported to enter, or remain in work, or which parts of the country will see these outcomes as a result of this expansion of IPS. However, the IPS model is recognised both in the UK and internationally as the most effective way to help individuals with SMI find and keep a job.</p> more like this
star this property answering member constituency Thurrock remove filter
star this property answering member printed Jackie Doyle-Price more like this
star this property grouped question UIN 186278 more like this
star this property question first answered
less than 2018-11-07T12:48:36.967Zmore like thisremove minimum value filter
star this property answering member
4065
star this property label Biography information for Jackie Doyle-Price more like this
star this property tabling member
1586
unstar this property label Biography information for Adam Afriyie more like this
1141381
star this property registered interest false more like this
star this property date less than 2019-07-23more like thismore than 2019-07-23
star this property answering body
Department of Health and Social Care more like this
star this property answering dept id 17 more like this
star this property answering dept short name Health and Social Care more like this
star this property answering dept sort name Health and Social Care more like this
star this property hansard heading MMR Vaccine more like this
star this property house id 1 more like this
star this property legislature
25259
star this property pref label House of Commons more like this
star this property question text To ask the Secretary of State for Health and Social Care, what steps he is taking to help ensure (a) transparency and (b) accountability in the process of manufacturing the MMR vaccine. more like this
star this property tabling member constituency Gravesham more like this
star this property tabling member printed
Adam Holloway more like this
star this property uin 280999 more like this
star this property answer
answer
unstar this property is ministerial correction false more like this
unstar this property date of answer less than 2019-07-25more like thismore than 2019-07-25
star this property answer text <p>Two Measles, Mumps and Rubella (MMR) vaccines are licensed for use in the United Kingdom: M-M-RVaxPro and Priorix. Both vaccines are on the National Health Service’s routine immunisation schedule. The quality, safety and efficacy of both M-M-RVaxPro and Priorix have been evaluated before they were given a Marketing Authorisation in Europe, and the Marketing Authorisation Holder for each vaccines is legally required to submit periodic safety update reports to the regulator, which are documents intended to provide an evaluation of the risk-benefit balance of a medicinal product at defined time points after its authorisation. The sites at which the products are manufactured are also required to undergo periodic inspections to ensure that they comply with Good Manufacturing Practices. Each batch of vaccines is tested by an official medicines control laboratory (OMCL). OMCL testing is independent of and in addition to the manufacturer’s testing. These procedures ensure that the MMR vaccines available in the UK are safe and efficacious and that the manufacturers/Marketing Authorisation holders are held accountable for their products.</p><p>A European Public Assessment Report (EPAR) for M-M-RVaxPro is available at the following link:</p><p><a href="https://www.ema.europa.eu/en/documents/scientific-discussion/m-m-rvaxpro-epar-scientific-discussion_en.pdf" target="_blank">https://www.ema.europa.eu/en/documents/scientific-discussion/m-m-rvaxpro-epar-scientific-discussion_en.pdf</a></p><p>Priorix was approved before public assessment reports were a requirement. The EPAR for M-M-RVaxPro contains a general summary of the manufacturing information that was provided during the assessment process; however, the specific details of the manufacturing process are confidential.</p>
star this property answering member constituency Thurrock remove filter
star this property answering member printed Jackie Doyle-Price more like this
star this property question first answered
less than 2019-07-25T16:38:57.347Zmore like thismore than 2019-07-25T16:38:57.347Z
star this property answering member
4065
star this property label Biography information for Jackie Doyle-Price more like this
star this property tabling member
1522
unstar this property label Biography information for Adam Holloway more like this
1141380
star this property registered interest false more like this
star this property date less than 2019-07-23more like thismore than 2019-07-23
star this property answering body
Department of Health and Social Care more like this
star this property answering dept id 17 more like this
star this property answering dept short name Health and Social Care more like this
star this property answering dept sort name Health and Social Care more like this
star this property hansard heading MMR Vaccine: Safety more like this
star this property house id 1 more like this
star this property legislature
25259
star this property pref label House of Commons more like this
star this property question text To ask the Secretary of State for Health and Social Care, what steps he is taking to maintain and improve pharmacovigilance in relation to the MMR vaccine. more like this
star this property tabling member constituency Gravesham more like this
star this property tabling member printed
Adam Holloway more like this
star this property uin 280998 more like this
star this property answer
answer
unstar this property is ministerial correction false more like this
unstar this property date of answer less than 2019-07-25more like thismore than 2019-07-25
star this property answer text <p>As with all vaccines and medicines, the safety of the Measles, Mumps and Rubella (MMR) vaccine remains under continual review by the Medicines and Healthcare products Regulatory Agency (MHRA). The MHRA uses all available sources of evidence in pharmacovigilance, including regular review of suspected adverse reactions submitted through the Yellow Card Scheme, data from clinical and epidemiological studies, the medical literature and information from pharmaceutical companies and other worldwide regulatory authorities. The MHRA’s processes and data analysis systems are regularly evaluated to ensure optimal performance in monitoring the safety of vaccines and medicines.</p><p>The balance of benefits and risks of MMR vaccine remains overwhelmingly favourable.</p> more like this
star this property answering member constituency Thurrock remove filter
star this property answering member printed Jackie Doyle-Price more like this
star this property question first answered
less than 2019-07-25T16:35:38.84Zmore like thismore than 2019-07-25T16:35:38.84Z
star this property answering member
4065
star this property label Biography information for Jackie Doyle-Price more like this
star this property tabling member
1522
unstar this property label Biography information for Adam Holloway more like this
1054830
star this property registered interest false more like this
star this property date less than 2019-02-04more like thismore than 2019-02-04
star this property answering body
Department of Health and Social Care more like this
star this property answering dept id 17 more like this
star this property answering dept short name Health and Social Care more like this
star this property answering dept sort name Health and Social Care more like this
star this property hansard heading Stamaril more like this
star this property house id 1 more like this
star this property legislature
25259
star this property pref label House of Commons more like this
star this property question text To ask the Secretary of State for Health and Social Care, if he will make an assessment of the potential merits of including psychosis in the list of potential side effects published on the use of Stamaril as a vaccine for yellow fever. more like this
star this property tabling member constituency Gravesham more like this
star this property tabling member printed
Adam Holloway more like this
star this property uin 216213 more like this
star this property answer
answer
unstar this property is ministerial correction false more like this
unstar this property date of answer less than 2019-02-12more like thismore than 2019-02-12
star this property answer text <p>As with all vaccines and medicines, the Medicines and Healthcare products Regulatory Agency (MHRA) closely monitors the safety of Stamaril yellow fever vaccine. The MHRA takes advice from the Government's independent scientific advisory body, the Commission on Human Medicines, when evaluating the risks and benefits of medicines and vaccines.</p><p> </p><p>The Marketing Authorisation Holder for Stamaril, Sanofi Pasteur, has statutory obligations to continuously monitor the safety, and balance of benefits and risks, of the vaccine.</p><p> </p><p>The potential risks of Stamaril are described in the prescribing information, the Summary of Product Characteristics, and the information for vaccine recipients, the Patient Information Leaflet. A recognised, very rare risk of Stamaril vaccine is Yellow Fever Vaccine-Associated Neurotropic Disease, known as YEL-AND. Whilst the symptoms of YEL-AND can include confusion and acute focal neurological deficits (e.g. affecting motor co-ordination), this is not typically associated with psychosis or other long-term psychiatric disorders.</p><p> </p><p>Further to other recent reports of serious suspected adverse reactions in United Kingdom travellers, the MHRA is in the process of further reviewing the balance of benefits and risks of Yellow Fever vaccine, which will include an analysis of neuropsychiatric events.</p>
star this property answering member constituency Thurrock remove filter
star this property answering member printed Jackie Doyle-Price more like this
star this property grouped question UIN
216210 more like this
216211 more like this
star this property question first answered
less than 2019-02-12T17:04:11.833Zmore like thismore than 2019-02-12T17:04:11.833Z
star this property answering member
4065
star this property label Biography information for Jackie Doyle-Price more like this
star this property tabling member
1522
unstar this property label Biography information for Adam Holloway more like this
1054828
star this property registered interest false more like this
star this property date less than 2019-02-04more like thismore than 2019-02-04
star this property answering body
Department of Health and Social Care more like this
star this property answering dept id 17 more like this
star this property answering dept short name Health and Social Care more like this
star this property answering dept sort name Health and Social Care more like this
star this property hansard heading Stamaril more like this
star this property house id 1 more like this
star this property legislature
25259
star this property pref label House of Commons more like this
star this property question text To ask the Secretary of State for Health and Social Care, what representations he has made to Sanofi Pasteur on ensuring that new technology is developed to eliminate the risks of adverse events, including psychosis, from the use of the vaccine Stamaril. more like this
star this property tabling member constituency Gravesham more like this
star this property tabling member printed
Adam Holloway more like this
star this property uin 216211 more like this
star this property answer
answer
unstar this property is ministerial correction false more like this
unstar this property date of answer less than 2019-02-12more like thismore than 2019-02-12
star this property answer text <p>As with all vaccines and medicines, the Medicines and Healthcare products Regulatory Agency (MHRA) closely monitors the safety of Stamaril yellow fever vaccine. The MHRA takes advice from the Government's independent scientific advisory body, the Commission on Human Medicines, when evaluating the risks and benefits of medicines and vaccines.</p><p> </p><p>The Marketing Authorisation Holder for Stamaril, Sanofi Pasteur, has statutory obligations to continuously monitor the safety, and balance of benefits and risks, of the vaccine.</p><p> </p><p>The potential risks of Stamaril are described in the prescribing information, the Summary of Product Characteristics, and the information for vaccine recipients, the Patient Information Leaflet. A recognised, very rare risk of Stamaril vaccine is Yellow Fever Vaccine-Associated Neurotropic Disease, known as YEL-AND. Whilst the symptoms of YEL-AND can include confusion and acute focal neurological deficits (e.g. affecting motor co-ordination), this is not typically associated with psychosis or other long-term psychiatric disorders.</p><p> </p><p>Further to other recent reports of serious suspected adverse reactions in United Kingdom travellers, the MHRA is in the process of further reviewing the balance of benefits and risks of Yellow Fever vaccine, which will include an analysis of neuropsychiatric events.</p>
star this property answering member constituency Thurrock remove filter
star this property answering member printed Jackie Doyle-Price more like this
star this property grouped question UIN
216210 more like this
216213 more like this
star this property question first answered
less than 2019-02-12T17:04:11.787Zmore like thismore than 2019-02-12T17:04:11.787Z
star this property answering member
4065
star this property label Biography information for Jackie Doyle-Price more like this
star this property tabling member
1522
unstar this property label Biography information for Adam Holloway more like this
1054826
star this property registered interest false more like this
star this property date less than 2019-02-04more like thismore than 2019-02-04
star this property answering body
Department of Health and Social Care more like this
star this property answering dept id 17 more like this
star this property answering dept short name Health and Social Care more like this
star this property answering dept sort name Health and Social Care more like this
star this property hansard heading Stamaril more like this
star this property house id 1 more like this
star this property legislature
25259
star this property pref label House of Commons more like this
star this property question text To ask the Secretary of State for Health and Social Care, if he will make representations to Sanofi Pasteur on undertaking new research into the risks of adverse events, including psychosis, from using the vaccine Stamaril. more like this
star this property tabling member constituency Gravesham more like this
star this property tabling member printed
Adam Holloway more like this
star this property uin 216210 more like this
star this property answer
answer
unstar this property is ministerial correction false more like this
unstar this property date of answer less than 2019-02-12more like thismore than 2019-02-12
star this property answer text <p>As with all vaccines and medicines, the Medicines and Healthcare products Regulatory Agency (MHRA) closely monitors the safety of Stamaril yellow fever vaccine. The MHRA takes advice from the Government's independent scientific advisory body, the Commission on Human Medicines, when evaluating the risks and benefits of medicines and vaccines.</p><p> </p><p>The Marketing Authorisation Holder for Stamaril, Sanofi Pasteur, has statutory obligations to continuously monitor the safety, and balance of benefits and risks, of the vaccine.</p><p> </p><p>The potential risks of Stamaril are described in the prescribing information, the Summary of Product Characteristics, and the information for vaccine recipients, the Patient Information Leaflet. A recognised, very rare risk of Stamaril vaccine is Yellow Fever Vaccine-Associated Neurotropic Disease, known as YEL-AND. Whilst the symptoms of YEL-AND can include confusion and acute focal neurological deficits (e.g. affecting motor co-ordination), this is not typically associated with psychosis or other long-term psychiatric disorders.</p><p> </p><p>Further to other recent reports of serious suspected adverse reactions in United Kingdom travellers, the MHRA is in the process of further reviewing the balance of benefits and risks of Yellow Fever vaccine, which will include an analysis of neuropsychiatric events.</p>
star this property answering member constituency Thurrock remove filter
star this property answering member printed Jackie Doyle-Price more like this
star this property grouped question UIN
216211 more like this
216213 more like this
star this property question first answered
less than 2019-02-12T17:04:11.727Zmore like thismore than 2019-02-12T17:04:11.727Z
star this property answering member
4065
star this property label Biography information for Jackie Doyle-Price more like this
star this property tabling member
1522
unstar this property label Biography information for Adam Holloway more like this
1054839
star this property registered interest false more like this
star this property date less than 2019-02-04more like thismore than 2019-02-04
star this property answering body
Department of Health and Social Care more like this
star this property answering dept id 17 more like this
star this property answering dept short name Health and Social Care more like this
star this property answering dept sort name Health and Social Care more like this
star this property hansard heading Stamaril more like this
star this property house id 1 more like this
star this property legislature
25259
star this property pref label House of Commons more like this
star this property question text To ask the Secretary of State for Health and Social Care, what information he holds on research into safer alternatives to the Stamaril vaccine; and if the Government will provide funding for such research. more like this
star this property tabling member constituency Gravesham more like this
star this property tabling member printed
Adam Holloway more like this
star this property uin 216216 more like this
star this property answer
answer
unstar this property is ministerial correction false more like this
unstar this property date of answer less than 2019-02-12more like thismore than 2019-02-12
star this property answer text <p>The Medical Research Council has an active study to assess the safety and immunogenicity of yellow fever vaccine dose sparing strategies for campaign and programmatic use. The study seeks to determine whether using a fractional dose of the normal yellow fever vaccine in infants provides sufficient protection against yellow fever compared with the normal dose of vaccine and whether altering the route of administration affects vaccine safety.</p> more like this
star this property answering member constituency Thurrock remove filter
star this property answering member printed Jackie Doyle-Price more like this
star this property question first answered
less than 2019-02-12T16:59:08.097Zmore like thismore than 2019-02-12T16:59:08.097Z
star this property answering member
4065
star this property label Biography information for Jackie Doyle-Price more like this
star this property tabling member
1522
unstar this property label Biography information for Adam Holloway more like this
1054841
star this property registered interest false more like this
star this property date less than 2019-02-04more like thismore than 2019-02-04
star this property answering body
Department of Health and Social Care more like this
star this property answering dept id 17 more like this
star this property answering dept short name Health and Social Care more like this
star this property answering dept sort name Health and Social Care more like this
star this property hansard heading Drugs: Side Effects more like this
star this property house id 1 more like this
star this property legislature
25259
star this property pref label House of Commons more like this
star this property question text To ask the Secretary of State for Health and Social Care, whether he has made a recent assessment of the effectiveness of the regulatory regime in ensuring that drug companies continuously take steps to minimise the risks from their products. more like this
star this property tabling member constituency Gravesham more like this
star this property tabling member printed
Adam Holloway more like this
star this property uin 216217 more like this
star this property answer
answer
unstar this property is ministerial correction false more like this
unstar this property date of answer less than 2019-02-12more like thismore than 2019-02-12
star this property answer text <p>Holders of marketing authorisations are responsible for on-going monitoring of the safety of the medicinal products they place on the market. Additionally, the safety profile of all medicinal products is continually reviewed by the Medicines and Healthcare products Regulatory Agency (MHRA) to determine whether there are new risks, if risks have changed, and if any additional risk minimising measures or other regulatory action is required.</p><p> </p><p>Since 2012 it has been a legal requirement for both marketing authorisation holders and medicines regulators to monitor the effectiveness of all such risk minimising measures to determine whether they have had the desired effect. Depending on the findings, further action to minimise risk may be taken.</p><p> </p><p>Recent reviews of the impact of regulatory interventions have been conducted by the MHRA and across the European regulatory network, and further evaluation of the effectiveness of the regulatory regimen in the European Union is ongoing.</p>
star this property answering member constituency Thurrock remove filter
star this property answering member printed Jackie Doyle-Price more like this
star this property question first answered
less than 2019-02-12T16:53:58.243Zmore like thismore than 2019-02-12T16:53:58.243Z
star this property answering member
4065
star this property label Biography information for Jackie Doyle-Price more like this
star this property tabling member
1522
unstar this property label Biography information for Adam Holloway more like this